256 related articles for article (PubMed ID: 29681433)
1. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
[TBL] [Abstract][Full Text] [Related]
2. Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
Fukuda T; Kuribayashi T; Takano R; Sasaki K; Tsuji T; Niitsu Y; Ishii K; Hashimoto M; Baba D; Ito S; Tanaka N
Bioorg Med Chem Lett; 2024 Aug; 108():129799. PubMed ID: 38754564
[TBL] [Abstract][Full Text] [Related]
3. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
[TBL] [Abstract][Full Text] [Related]
5. [(4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl)-amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues.
Hong YR; Kim HT; Lee SC; Ro S; Cho JM; Kim IS; Jung YH
Bioorg Med Chem Lett; 2013 Nov; 23(21):5953-7. PubMed ID: 24042008
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Sakashita M; Tanaka T; Nangaku M
Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.
Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
Eur J Med Chem; 2022 Aug; 238():114479. PubMed ID: 35675755
[TBL] [Abstract][Full Text] [Related]
8. Enarodustat: First Approval.
Markham A
Drugs; 2021 Jan; 81(1):169-174. PubMed ID: 33320297
[TBL] [Abstract][Full Text] [Related]
9. TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation.
Kato S; Takayama N; Takano H; Koretsune H; Koizumi C; Kunioka EI; Uchida S; Takahashi T; Yamamoto K
Eur J Pharmacol; 2018 Nov; 838():138-144. PubMed ID: 30179610
[TBL] [Abstract][Full Text] [Related]
10. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
Böttcher M; Lentini S; Arens ER; Kaiser A; van der Mey D; Thuss U; Kubitza D; Wensing G
Br J Clin Pharmacol; 2018 Jul; 84(7):1557-1565. PubMed ID: 29575006
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia.
Xu J; Ding X; Fu Y; Meng Q; Wang L; Zhang M; Xu C; Chen S; Aliper A; Ren F; Zhavoronkov A; Ding X
J Med Chem; 2024 Jan; 67(2):1393-1405. PubMed ID: 38189253
[TBL] [Abstract][Full Text] [Related]
12. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K
J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986
[TBL] [Abstract][Full Text] [Related]
13. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
Joharapurkar AA; Pandya VB; Patel VJ; Desai RC; Jain MR
J Med Chem; 2018 Aug; 61(16):6964-6982. PubMed ID: 29712435
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
15. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia.
Yu Y; Yang F; Yu Q; Liu S; Wu C; Su K; Yang L; Bao X; Li Z; Li X; Zhang X
J Med Chem; 2021 Dec; 64(23):17384-17402. PubMed ID: 34709043
[TBL] [Abstract][Full Text] [Related]
17. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
Wu Y; Jiang Z; You Q; Zhang X
Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
19. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
20. Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.
Debenham JS; Madsen-Duggan C; Clements MJ; Walsh TF; Kuethe JT; Reibarkh M; Salowe SP; Sonatore LM; Hajdu R; Milligan JA; Visco DM; Zhou D; Lingham RB; Stickens D; DeMartino JA; Tong X; Wolff M; Pang J; Miller RR; Sherer EC; Hale JJ
J Med Chem; 2016 Dec; 59(24):11039-11049. PubMed ID: 28002958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
